In patients with rheumatoid arthritis, rituximab (Rituxan, Genentech, Inc.), alone or in combination with either methotrexate (MTX) or cyclophosphamide (CTX), appears to result in significant clinical benefit, new research suggests.
Rituximab, indicated for the treatment of relapsed or refractory low-grade or follicular, CD20+ B-cell non-Hodgkin’s lymphoma, is a monoclonal antibody targeted to the CD20 antigen on the surface of B-lymphocytes.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!